domperidone has been researched along with Breast Neoplasms in 4 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 9.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 5.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "Domperidone was given twice a day for one week." | 1.27 | [Effect of combined use of adrenocortical hormones and domperidone as anti-emetics during cisplatin therapy]. ( Hirose, Y; Matsushita, T; Mise, K; Nakanishi, M; Shirosaki, H; Tanaka, T; Yamaoto, T, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stricker, HM | 1 |
| Rommerswinkel, N | 1 |
| Keil, S | 1 |
| Gnoth, SA | 1 |
| Niggemann, B | 1 |
| Dittmar, T | 1 |
| Ye, Q | 1 |
| Kantonen, S | 1 |
| Gomez-Cambronero, J | 1 |
| Roila, F | 1 |
| Tonato, M | 1 |
| Basurto, C | 1 |
| Minotti, V | 1 |
| Ballatori, E | 1 |
| del Favero, A | 1 |
| Tanaka, T | 1 |
| Nakanishi, M | 1 |
| Hirose, Y | 1 |
| Mise, K | 1 |
| Matsushita, T | 1 |
| Yamaoto, T | 1 |
| Shirosaki, H | 1 |
1 trial available for domperidone and Breast Neoplasms
| Article | Year |
|---|---|
Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
3 other studies available for domperidone and Breast Neoplasms
| Article | Year |
|---|---|
The phospholipase D inhibitor FIPI potently blocks EGF-induced calcium signaling in human breast cancer cells.
Topics: Breast Neoplasms; Calcium; Calcium Signaling; Cell Line, Tumor; Cell Movement; Domperidone; Enzyme I | 2021 |
Serum deprivation confers the MDA-MB-231 breast cancer line with an EGFR/JAK3/PLD2 system that maximizes cancer cell invasion.
Topics: Apigenin; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Culture Media, Serum | 2013 |
[Effect of combined use of adrenocortical hormones and domperidone as anti-emetics during cisplatin therapy].
Topics: Adult; Aged; Breast Neoplasms; Cisplatin; Domperidone; Drug Therapy, Combination; Esophageal Neoplas | 1985 |